Smithfield Trust’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-60
| Closed | -$8K | – | 1066 |
|
|
2024
Q4 | $8K | Hold |
60
| – | – | ﹤0.01% | 907 |
|
|
2024
Q3 | $6K | Hold |
60
| – | – | ﹤0.01% | 926 |
|
|
2024
Q2 | $8K | Hold |
60
| – | – | ﹤0.01% | 859 |
|
|
2024
Q1 | $8K | Hold |
60
| – | – | ﹤0.01% | 875 |
|
|
2023
Q4 | $8K | Hold |
60
| – | – | ﹤0.01% | 862 |
|
|
2023
Q3 | $6K | Hold |
60
| – | – | ﹤0.01% | 888 |
|
|
2023
Q2 | $6K | Hold |
60
| – | – | ﹤0.01% | 900 |
|
|
2023
Q1 | $6K | Hold |
60
| – | – | ﹤0.01% | 870 |
|
|
2022
Q4 | $7K | Hold |
60
| – | – | ﹤0.01% | 842 |
|
|
2022
Q3 | $6K | Hold |
60
| – | – | ﹤0.01% | 876 |
|
|
2022
Q2 | $6K | Hold |
60
| – | – | ﹤0.01% | 931 |
|
|
2022
Q1 | $6K | Hold |
60
| – | – | ﹤0.01% | 954 |
|
|
2021
Q4 | $6K | Hold |
60
| – | – | ﹤0.01% | 963 |
|
|
2021
Q3 | $6K | Hold |
60
| – | – | ﹤0.01% | 972 |
|
|
2021
Q2 | $6K | Sell |
60
-10
| -14% | -$1K | ﹤0.01% | 955 |
|
|
2021
Q1 | $7K | Hold |
70
| – | – | ﹤0.01% | 940 |
|
|
2020
Q4 | $7K | Hold |
70
| – | – | ﹤0.01% | 908 |
|
|
2020
Q3 | $7K | Sell |
70
-14
| -17% | -$1.4K | ﹤0.01% | 850 |
|
|
2020
Q2 | $10K | Buy |
84
+14
| +20% | +$1.67K | ﹤0.01% | 742 |
|
|
2020
Q1 | $6K | Hold |
70
| – | – | ﹤0.01% | 753 |
|
|
2019
Q4 | $8K | Hold |
70
| – | – | ﹤0.01% | 729 |
|
|
2019
Q3 | $6K | Hold |
70
| – | – | ﹤0.01% | 806 |
|
|
2019
Q2 | $6K | Hold |
70
| – | – | ﹤0.01% | 786 |
|
|
2019
Q1 | $6K | Hold |
70
| – | – | ﹤0.01% | 742 |
|
|
2018
Q4 | $5K | Hold |
70
| – | – | ﹤0.01% | 751 |
|
|
2018
Q3 | $9K | Hold |
70
| – | – | ﹤0.01% | 743 |
|
|
2018
Q2 | $7K | Buy |
+70
| New | +$7K | ﹤0.01% | 779 |
|